|Bid||10.21 x 1400|
|Ask||10.39 x 1400|
|Day's Range||9.82 - 10.77|
|52 Week Range||5.84 - 26.99|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||14.37|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 16, 2022|
|1y Target Est||N/A|
Siga Technologies said on Thursday it has won a new contract for its oral antiviral drug, Tpoxx, worth up to $10.7 million from the U.S. Department of Defense as the country stocks up on the treatment amid a monkeypox outbreak. Siga said it aims to deliver $5.1 million worth of oral Tpoxx drugs this year, with the remaining subject to the discretion of the department. The new contract follows another one from the DoD earlier this year for the procurement of $7.4 million worth of oral Tpoxx, with all drugs expected to be delivered this year, the company said.
- In 2022, the U.S. Department of Defense has Awarded Procurement Contracts for the Purchase of up to $18.1 Million of Oral TPOXX –NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procurement of up to $10.7 million of oral TPOXX (Contract number: W911SR22C0051), of which $5.1 mi
Every investor in SIGA Technologies, Inc. ( NASDAQ:SIGA ) should be aware of the most powerful shareholder groups. And...